Every Form 4 that Aspira Womens Health Inc (AWHL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AWHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AWHL filings page.
Aspira Women's Health Inc. reported that Chief Financial Officer John Strahley received a corrected grant of 70,000 employee stock options to buy common stock at an exercise price of $0.50 per share, expiring June 16, 2036. 17,500 options vest on July 26, 2026, with the remaining shares vesting in equal monthly installments over the following nine months.
Aspira Women's Health Inc. reported that Chief Financial Officer John Strahley received a grant of employee stock options for 75,000 shares of common stock on June 16, 2026. The options have a $0.50 exercise price and expire on June 16, 2036. According to the vesting schedule, 18,750 options vest on July 26, 2026, with the remaining options vesting in equal monthly installments over the following nine months. No open-market purchases or sales were reported.
Aspira Women's Health Inc. insider filing shows net buying activity by the Jack W. Schuler Living Trust, for which Jack W. Schuler serves as sole trustee and may be deemed to beneficially own the securities.
On June 5, 2026, the Living Trust purchased 222,222 shares of Common Stock at $0.45 per share and 300,000 Warrants (Right to Buy) for Common Stock with a $0.75 exercise price expiring in 2029. Following these transactions, the trust held 4,046,051 shares of Common Stock indirectly, while Schuler also held 6,536 Common shares and multiple warrant positions directly and indirectly.
Aspira Women's Health director Jeffrey K. Cohen reported changes in his holdings. The main event was an "other" transaction coded J on September 17, 2025, where 11,112 shares of common stock at $0.45 per share were acquired as payment from another party in settlement of another property.
After this, Cohen directly held 386,018 common shares and indirectly held 71,010 shares through his spouse. He also held warrants to buy 450,318 common shares at $0.35 per share expiring on March 5, 2031, and warrants to buy 41,667 shares at $0.75 per share expiring on September 17, 2030.
Aspira Women's Health director Fraser John D filed an amended Form 4 to correct the number of shares indirectly held through Seamark Capital and the presentation of his warrant holdings as of September 17, 2025. He bought 16,389 shares of common stock at $0.45 per share and acquired a warrant for 12,292 underlying shares with a $0.75 exercise price. Following these transactions, he directly owns 566,393 common shares and holds 287,769 shares indirectly via Seamark Capital. He also holds warrants covering 900,633 shares at a $0.35 exercise price expiring in 2031 and 68,627 shares at a $2.25 exercise price expiring in 2027, plus the new warrant for 12,292 shares expiring in 2030.
Aspira Women's Health director Jeffrey K. Cohen reported open-market purchases of common stock and warrants in an amended Form 4. On September 17, 2025, he bought 55,556 shares of common stock at $0.45 per share, bringing his directly held common stock position to 374,906 shares.
He also purchased a warrant covering 41,667 shares of common stock with an exercise price of $0.75 per share, expiring on September 17, 2030, and now holds 41,667 of these warrants directly. Separately, 71,010 shares of common stock are reported as held indirectly through his spouse.
The filing further shows a direct warrant position with an exercise price of $0.35 per share, expiring on March 5, 2031, relating to 450,318 underlying shares of common stock. According to the footnote, this amendment corrects prior disclosures about the number and nature of shares and warrants held on September 17, 2025.
Aspira Women's Health Inc. director Cynthia Hundorfean reported receiving a stock option grant. On 12/02/2025, she was granted options to buy 238,085 shares of Aspira common stock at an exercise price of $0.35 per share. These options become exercisable on 12/02/2025 and expire on 12/02/2035. Following this grant, she beneficially owns 238,085 derivative securities directly.
Aspira Women's Health Inc. reported an insider equity award for one of its directors. On 12/02/2025, the reporting person received a stock option, described as a right to buy up to 314,811 shares of the company’s common stock at an exercise price of $0.35 per share. The option becomes exercisable on the same date, 12/02/2025, and is scheduled to expire on 12/02/2035.
Following this grant, the reporting person beneficially owns 314,811 derivative securities directly in the form of this stock option. The form is signed by /s/ John D. Fraser, indicating his role as the reporting person and confirming the director status in relation to Aspira Women's Health.
Aspira Women's Health Inc. director reports new stock option grant. A director of Aspira Women's Health Inc. received a stock option on 12/02/2025 covering 135,592 shares of common stock. The option has an exercise price of $0.35 per share, is listed as exercisable on 12/02/2025, and expires on 12/02/2035. After this transaction, the director beneficially owns 135,592 derivative securities, held directly.
Aspira Women's Health Inc. reported an insider equity award for director Winfred Parnell. On 12/02/2025, Parnell received a stock option to buy 185,178 shares of common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. After this award, Parnell beneficially owned 185,178 derivative securities directly.
Aspira Women's Health Inc. director Jeffrey Cohen reported a new stock option grant. On 12/02/2025, he received an option to buy 213,518 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option is exercisable starting on the grant date and expires on 12/02/2035. After this grant, Cohen beneficially owns 213,518 derivative securities directly in the form of this stock option, giving him potential future ownership if he chooses to exercise.
Aspira Women's Health Inc. reported an insider equity award for a director. A Form 4 filing shows that on 12/02/2025 a director received a stock option (right to buy) covering 198,097 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. Following this grant, the director beneficially owns 198,097 derivative securities, held in direct ownership form.
Aspira Women's Health Inc. insider purchase and holdings update. Director Jack W. Schuler, as sole trustee of the Jack W. Schuler Living Trust, reported purchases and existing holdings in AWHL securities. On 09/17/2025 he purchased 1,111,111 shares of common stock at $0.45 per share and now beneficially owns 3,823,829 shares indirectly through the Living Trust. The filing also reports warrants totaling 2,661,422 underlying common shares across multiple strike prices and expirations, including an acquisition of 833,333 warrants exercisable at $0.75 (expiring 09/17/2030). A small disposition of 6,536 common shares and a prior disposal of 6,536 warrants at $2.25 are noted. The report is signed by Jack W. Schuler on 09/18/2025.
Jeffrey K. Cohen, a director of Aspira Women's Health Inc. (AWHL), reported insider purchases on 09/17/2025. He acquired 55,556 shares of common stock at $0.45 per share and received 41,667 warrants exercisable immediately and expiring 09/17/2030, each warrant underlying one share. Following the reported transactions, the filing shows 375,697 shares beneficially owned indirectly (via HealthView Asset Management) and 60,913 shares indirectly by spouse.
John D. Fraser, a director of Aspira Women's Health Inc. (AWHL), reported purchases on 09/17/2025. He acquired 16,389 shares of common stock at $0.45 per share and purchased 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030) covering 12,292 shares. After these transactions he reports beneficial ownership of 566,393 shares directly and 291,554 indirectly through Seamark Capital; 981,549 derivative securities are shown as owned.